Medtronic (NYSE:MDT) Stock Rating Upgraded by Wall Street Zen

Medtronic (NYSE:MDT) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Friday.

A number of other equities research analysts also recently commented on the company. The Goldman Sachs Group set a $111.00 target price on Medtronic and gave the stock a “neutral” rating in a report on Wednesday, November 19th. Citigroup raised their price target on shares of Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Finally, Sanford C. Bernstein raised their target price on shares of Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Fourteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.28.

Medtronic Trading Down 0.4%

NYSE:MDT opened at $100.98 on Friday. The company has a market capitalization of $129.45 billion, a P/E ratio of 27.22, a PEG ratio of 2.66 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic has a 12 month low of $79.55 and a 12 month high of $106.33. The firm has a fifty day simple moving average of $99.44 and a 200-day simple moving average of $95.28.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same quarter last year, the business posted $1.26 EPS. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts anticipate that Medtronic will post 5.46 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Bridgewater Advisors Inc. increased its stake in shares of Medtronic by 10.2% in the 4th quarter. Bridgewater Advisors Inc. now owns 3,705 shares of the medical technology company’s stock valued at $372,000 after purchasing an additional 343 shares in the last quarter. Bingham Private Wealth LLC purchased a new position in Medtronic during the fourth quarter worth approximately $203,000. Farther Finance Advisors LLC grew its holdings in Medtronic by 5.8% in the fourth quarter. Farther Finance Advisors LLC now owns 71,699 shares of the medical technology company’s stock valued at $6,887,000 after purchasing an additional 3,957 shares during the period. Freestone Capital Holdings LLC increased its position in shares of Medtronic by 4.1% in the fourth quarter. Freestone Capital Holdings LLC now owns 25,166 shares of the medical technology company’s stock valued at $2,417,000 after buying an additional 996 shares in the last quarter. Finally, Natural Investments LLC increased its position in shares of Medtronic by 18.4% in the fourth quarter. Natural Investments LLC now owns 4,901 shares of the medical technology company’s stock valued at $470,000 after buying an additional 762 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).